Earnings Roundup: iAnthus, Can-Fite, Organigram, Bluma Wellness, Auxly
iAnthus Touts 82% YoY Revenue Growth, Names Interim COO
New York-based iAnthus Capital Holdings Inc. (CSE:IAN) (OTC:ITHUF) generated around $40.6 million in revenue during the third quarter of fiscal 2020. That's up by 17% sequentially and roughly 82% year-over-year.
The company disclosed a net loss of $9.7 million, compared to a $20.9 million loss in the previous quarter.
In addition, gross margin for the quarter went up to 62.9% from 54.8% in the second quarter.
Senior Vice President and Chief Administrative Officer Robert Galvin was promoted to Interim Chief Operating Officer. He replaces Patrick Tiernan, who has resigned.
Interim CEO Randy Maslow said Tiernan “played a key role in driving improvements to operating results and product development, as well as the difficult task of integrating the assets we acquired in the MPX transaction.”
Can-Fite Revenue Drops 67% YoY To $0.61M
The Petach Tikva, Israel-based biotech company confirmed its research and development expenses amounted to $9.05 million for the same period, versus $7.01 million for the corresponding period of last year.
In addition, general and administrative expenses were $2.14 million.
Other highlights from the period include FDA’s issuance of a “safe to proceed” notice for the company’s Investigational New Drug Application for a Phase II study of Piclidenoson in the treatment COVID-19 and finalization of the development of an assay to identify clinically active cannabis-derived compounds, to name a few.
“Piclidenoson’s anti-inflammatory and anti-viral properties make it a promising candidate in the fight against this pandemic,” Can-Fite CEO Pnina Fishman said.
Organigram Launches 40 New SKUs Since July, Q4 Revenue Hits $20.4M
The Moncton, New Brunswick-based company's gross revenue amounted to $25.4 million, up by 32% over the year.
Organigram also reported a negative adjusted EBITDA (a non-IFRS financial measure) of roughly 2.7 million, versus a loss of around 7.2 million in the corresponding quarter of 2019.
Sales and marketing and general and administrative expenses (excluding share-based compensation) amounted to $10.8 million, the company noted, while posting a negative gross margin of $28.8 million for the last quarter of this fiscal year.
Organigram also reported losing approximately $38.6 million for the quarter ended August 31.
Last month, Organigram invested an additional $2.5 million in a private biotechnology company Hyasynth Biologicals Inc. as the second tranche of financing under the $10 million debenture purchase deal.
The company recently announced an underwritten public offering of its units, securing CA$60.13 million in financing.
Bluma Wellness Reports $0.3M Net Income In Q3, One Plant Florida Achieves Same Dispensary Sales Growth Of 39.5%
The Toronto-based company also revealed its net income for the quarter was roughly $300,000, or $0.003 per basic and diluted share.
As of Sept. 30, Bluma had around $15.2 million, including cash and cash equivalents of approximately $300,000.
In addition, One Plant Florida's same dispensary sales rose 39.5% sequentially, including results from stores that were open more than six months.
Together with its parent company – Bluma – OPF has been scaling up its operations.
Beady Cobb, the company's CEO, recently told Benzinga they intend to "open four additional One Plant Florida retail locations and/or delivery hubs in Avon Park, Orlando (Fern Park), North Miami and Bonita Springs by the end of 2020, pending receipt of all required regulatory approvals from the Florida OMMU."
Auxly Sees 85% Revenue Sequqntial Growth, Generates $12.6M In Cannabis Revenue
Auxly Cannabis Group Inc. (TSX.V – XLY) (OTCQX:CBWTF) released third-quarter earnings, revealing it has generated $13.4 million in revenue, including $12.6 million of cannabis net revenues. That’s an 85% increase from the prior period.
The company posted a negative adjusted EBITDA of $6.8 million, as opposed to a loss of $11.05 million in the corresponding quarter of last year.
Auxly also disclosed its selling, general and administrative expenses dropped to $11.4 million.
The company also increased its cash position by $20 million, including a $12 million bought deal offering of its units it recently upsized and $8 million non-dilutive financings.
Last month, Auxly named Genevieve Young the board’s chairman, replacing Chuck Rifici, its founder and former CEO, on the position.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.